Treatment for CD117-Negative GIST
For CD117-negative GIST, confirm the diagnosis with DOG1 immunostaining and molecular testing for PDGFRA mutations, then treat with avapritinib if PDGFRA D842V mutation is present, or standard imatinib if other PDGFRA mutations are found 1.
Diagnostic Confirmation First
CD117 negativity does not exclude GIST. Approximately 5% of GISTs are CD117-negative but express DOG1 (discovered on GIST-1), which is a more sensitive marker 2. Before determining treatment:
- Perform DOG1 immunostaining - this will be positive in most CD117-negative GISTs
- Obtain molecular testing to identify the specific mutation (PDGFRA vs KIT vs other)
The molecular biology examination is critical here because CD117-negative GISTs often harbor PDGFRA mutations rather than KIT mutations 2.
Treatment Algorithm Based on Mutation Status
If PDGFRA D842V Mutation is Present:
Avapritinib is the most effective treatment, achieving >90% response rates with duration of response exceeding 70% at 1 year 1. This is a Level III, A recommendation with ESCAT score I-B 1.
- Standard imatinib is not effective for PDGFRA D842V mutations 3, 1
- Avapritinib specifically targets this mutation
- Important caveat: Watch for neurocognitive toxicity, brain bleeds, and seizures - these must be recognized early 1
- Access barrier: Not currently approved by NICE; requires individual funding request in NHS settings 3
If Other PDGFRA Mutations (Non-D842V):
Use standard imatinib 400 mg daily - these mutations remain sensitive to imatinib 1. Continue treatment indefinitely until progression or intolerance.
If SDH-Deficient GIST:
There may be benefit from sunitinib or regorafenib, though evidence is limited 1. Temozolomide is under investigation with preliminary promising results.
If NTRK Rearrangement:
Use NTRK inhibitors: larotrectinib or entrectinib (Level III, A; ESCAT score I-C) 1.
If BRAF Mutation:
Consider BRAF inhibitors or BRAF-MEK inhibitor combinations (Level V, B; ESCAT score III-A) 1.
Surgical Considerations
For localized, resectable CD117-negative GIST:
- Complete surgical resection (R0) remains the primary treatment if the tumor is resectable 1
- Lymphadenectomy is not necessary as GISTs rarely metastasize to lymph nodes 4
- Surgery should aim for complete removal without capsule rupture
Common Pitfalls to Avoid
- Don't abandon the GIST diagnosis just because CD117 is negative - always check DOG1 and obtain molecular testing
- Don't use standard imatinib for PDGFRA D842V mutations - it won't work and delays appropriate treatment
- Don't miss the neurocognitive side effects of avapritinib - early recognition is essential for treatment continuation
- Don't forget that molecular testing drives treatment selection in CD117-negative cases more than in typical GISTs